Critical temperature ranges of hypothermia-induced platelet activation: Possible implications for cooling patients in cardiac surgery

Summary

Cooling of the patient is routinely applied in cardiac surgery to protect organs against ischemia. Hypothermia induces activation of platelets, but the effects of temperatures such as used during cardiac surgery are not well described. To investigate this in an in-vitro study heparinized whole blood was incubated at different temperatures (37°C, 34.5°C, 32°C, 29.5°C, 27°C, 24.5°C, 22°C, 19.5°C and 17°C).The effect of these temperatures on aggregation, P-selectin expression, GP IIb/IIIa activation and platelet microparticle (PMP) formation of unstimulated and ADP-stimulated platelets of 36 subjects was evaluated in flow cytometry. A four-parametric logistic model was fitted to depict the temperature effect on platelet parameters. Lower temperatures increased aggregates, P-selectin expression, and GP IIb/IIIa activation. The number of PMPs decreases with hypothermia. Additional experiments revealed a slight influence of heparin on platelet P-selectin expression but excluded an effect of this anticoagulant on the other evaluated parameters. Threshold temperatures, which mark 5% changes of platelet parameters compared to values at 37°C, were calculated. On ADP-stimulated platelets the thresholds for P-selectin expression and GP IIb/IIIa activation are 34.0°C and 36.4°C, respectively, and lie in the temperature range routinely applied in cardiac surgery. Hypothermia- induced platelet activation may develop in most patients undergoing cardiac surgery, possibly resulting in thromboembolic events, coagulation defects, and proinflammatory leukocyte bridging by P-selectin bearing platelets and PMPs. These findings suggest that pharmacological protection of platelets against hypothermia-induced damage may be beneficial during cardiac surgery.

Keywords

Platelet physiology - cell-cell interactions - surgery - platelet glycoproteins

• References

• 1 Kirklin, Barratt-Boyes. Cardiac surgery 3^rd edition . USA, Elsevier Science. 2003
• 2 Hall MW, Goodman PD, Alston SM. et al. Hypothermia- induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation. Am J Hematol 2002; 69: 45-55.
• 3 Faraday N, Rosenfeld BA. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression. Anesthesiology 1998; 88: 1579-1585.
• 4 Doré M. Platelet-leukocyte interactions. Am Heart J 1998; 135: S146-151.
• 5 Straub A, Azevedo R, Beierlein W. et al. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest. Thromb Haemost 2005; 94: 115-122.
• 6 Abrams CS, Ellison N, Budzynski AZ. et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-138.
• 7 Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC. et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 3534-3541.
• 8 Gawaz M. Blood platelets. Stuttgart/New York: Thieme; 2001
• 9 Forlow SB, McEver RP, Nollert MU. et al. Leukocyteleukocyte interactions mediated by platelet microparticles under flow. Blood 2000; 95: 1317-1323.
• 10 Lindsey JK. Nonlinear models in medical statistics. Oxford, University Press: 2001
• 11 Fox JE, Austin CD, Reynolds CC. et al. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266: 13289-13295.
• 12 Tablin F, Oliver AE, Walker NJ. et al. Membrane phase transition of intact human platelets: correlation with cold-induced activation. J Cell Physiol 1996; 168: 305-313.
• 13 Winokur R, Hartwig JH. Mechanism of shape change in chilled human platelets. Blood 1995; 85: 1796-1804.
• 14 Peter K, Ahrens I, Schwarz M. et al. Distinct roles of ligand affinity and cytoskeletal anchorage in alphaIIbbeta3 (GP IIb/IIIa)-mediated cell aggregation and adhesion. Platelets 2004; 15: 427-438.
• 15 Takano K, Asazuma N, Satoh K. et al. Collagen-induced generation of platelet-derived microparticles in whole blood is dependent on ADP released from red blood cells and calcium ions. Platelets 2004; 15: 223-229.
• 16 Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 2145-2152.
• 17 Hall MW, Goodman PD, Solen KA. et al. Formation of occlusive platelet aggregates in whole blood caused by low concentrations of ADP. ASAIO J 2000; 46: 693-695.
• 18 Alkhamis TM, Beissinger RL, Chediak JR. Red blood cell effect on platelet adhesion and aggregation in low-stress shear flow. Myth or fact?. ASAIO Trans 1988; 34: 868-873.
• 19 Klein B, Faridi A, von Tempelhoff GF. et al. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res 2002; 108: 291-296.
• 20 Bizzarri F, Scolletta S, Tucci E. et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-1185.
• 21 Koster A, Chew DP, Kuebler W. et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91: 346-347.
• 22 Genoni M, Zeller D, Bertel O. et al. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery. J Thorac Cardiovasc Surg 2001; 122: 630-632.
• 23 Straub A, Azevedo R, Beierlein W. et al. Tirofiban (Aggrastat) protects platelets and decreases plateletgranulocyte binding in an extracorporeal circulation model. Thorac Cardiovasc Surg 2006; 54: 162-167.
• 24 Straub A, Wendel HP, Azevedo R. et al. The GP IIb/ IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 2005; 27: 617-621.
• 25 Schwarz M, Meade G, Stoll P. et al. Conformationspecific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006; 99: 25-33.